28th Annual Perinatal Conference

Complicated Mastitis

Cristiano Boneti, MD
Assistant Professor
Division of Breast Surgical Oncology
University of Arkansas for Medical Sciences

Disclosure

Nothing to Disclose

Historical Perspective

Nomenclature of Mammary Duct-associated Inflammatory Disease

Term/Pathognomonic Factor Investigators
Morbid condition of lactiferous duct Birkett, 1850

Mastitis obliterans Ingler, 1909

Payne et al. 19

Payne et al, 1943년
Chronic pyogenic mastitis
Chronic pyogenic mastitis
Stale milk mastitis
Cromar, 1921년
Varicocele tumor of the breast
Plasma cell mastitis
Adair, 1933년

Plasma cell mastitis
Involutional mammary duct ectasia with
periductal mastitis
Comedomastitis
Tice et al. 1948
Tice et al. 1948

Periductal mastitis Geschickter, 1948[™]
Chemical mastitis Stewart, 1950[™]
Fistulas of lactiferous ducts Zuska et al, 1951[™]
Mammary duct ectasia Haagensen, 1951[™]
Squamous metaplasia Patey and Thackray, 1958[™]


Secretory cystic disease of the breast Ingleby, 1942 Ingleby, 1942 Ingleby, 1942 Ingleby, 1942 Ingleby

Ingleby and Gershon-Cohen, 1960년 Periductal mastitis/duct ectasia Dixon, 1989년

Haagensen Theory

- · An evolutionary disease process
- Coined the term *mammary duct ectasia* (dilation of the subareolar terminal ducts)
- •Stages in the pathogenesis of subareolar abscess:
 - dilation of ducts + accumulation of debris (no inflammation)
 - periductal inflammation with necrosis
 - ·fibrosis

Mammary Duct—Associated Inflammatory Disease Sequence (MDAIDS) Normal breast Breast Is A Modified Sweat Gland Squamous Metaplasia + Duct Ectasia Degree Of Duct Ectasia Degree Of Duct Ectasia Degree Of Dust Ectasia





Initial changes · mild duct ectasia

- · foamy histiocytes with filling of duct lumens

- As the disease progresses
 major ducts exhibit increased ectasia
 - dense inspissation of secretions and periductal fibrosis


With infection


 abscess: predominant acute inflammatory infiltrate
 subacute or chronic: inflammatory exudate contains not only polymorphonuclear leukocytes but also lymphocytes, plasma cells, histiocytes, cell debris, and keratin

Normal anatomy Disease progression:

- · copious amounts of keratin
- obstruction by keratin plugs dilation of the duct and ampulla
- symptom include
 - · noncyclic mastalgia

 - nipple retractionand/or subareolar induration





Etiology

Hormonal Influences

Prolactin:

Estrogen:

• • estrogen activity (smoking) impairs the hormonally controlled integrity of the breast duct epithelium

Nutritional Factors

Vitamin A:

- deficiency induces keratinizing squamous metaplasia (head and neck, bronchi, uterus, and cervix)
- increasing evidence that vitamin A (or retinoids) have a significant effect on mammary duct epithelial cell proliferation and differentiation
- Vitamin A deficiency impairs blood clearance of bacteria and results in decreased phagocytic activity in vitro

Smoking


- 90% of recurrent breast abscess are exposed to cigarette smoke for many years
- •Risk of a recurrent subareolar breast abscess cigarette
- severe periductal inflammation is more often associated with heavy smoking (>10 cigarettes per day) and younger age
- increased incidence of mammary duct squamous metaplasia
- In the nonlactating breast, 7% of women secretions are mutagenic in the Ames tests and contain oxidized steroids an lipid peroxides. These metabolites might be responsible for direct cellular injury leading to reactive squamous metaplasia


Schafer P., Furrer C., Mermillod B.: An association of cigarette smoking with recurrent subareolar breast abscess. Int J Epidemiol 1988; 17:810-813.

Clinical Presentation

- Incidence is 👉
- Symptomatic MDAIDS = 20% Of Benign Conditions
- Peak Incidence 40 49 y

Holliday H., Hinton C.: Nipple discharge and duct ectasia. In: Blamey R.W., ed. Management of breast disease, London: Tindall; 1986.





Pain / Tenderness

- History Of Clinical Features, Character,
 Relationship To Menstruation, Site, Radiation,
 Duration And Associated Factors
- Physical Examination (Rule Out Muscleskeletal Pain)
- Mammography
- No Active Treatment Needed
 - Firm Supporting Bra 24 h/day
 - Nonsteroidal Anti-inflammatory Drug Or Mild Analgesic For Comfort

Nipple Discharge

- 8% to 84% of Pts
- Secretions Vary From Yellow,
- Brown, Red To Dark Green
 Consistency Varies From
- Consistency Varies From Serosanguineous To Toothpaste-like
- Initially Involve One Duct Or Segment Of The Breast
- May Involve Many Ducts
- May Be Bilateral



Rimsten A., Skoog V., Stenkvist B. On the significance of nipple discharge in the diagnosis of breast disease. Acta Chir Scand 1976; 142:513-518.

Leis Jr H.P., Plinik S., Dursi J., et al: Nipple discharge. Int Surg 1973; 58:162-165. Funderburk W.W., Syphax B. Evaluation of nipple discharge in benign and malignant diseases. Cancer 1969: 24:1290-1296.

Nipple Retraction

- Painless
- Rule Out Cancer
 - Length Of History
 - Onset Of Symptoms
- Can Develop After One Or Two Inflammatory Episodes
- Long-standing Nipple Inversion Is Benign And Easily Recognized
- Usually Bilateral
- > 40 y or Sudden Onset is Malignant Until Proved Otherwise

Clinical/Investiga tive Feature	Mammary Duct Ectasia of MDAIDS	Carcinoma
History	>1yr (present since puberty)	<1yr
Pain (%)	33	<10
Discharge	Creamy, green	Serous, blood stained
Nipple (examine carefully)	Partial, central, symmetrical retraction, often bilateral	Complete unilateral retraction with deformity of areola
Mass	Tender, firm lesion with discrete outline	Nontender, hard lesion with ragged outline
Cytology	Foam cells	Malignant glandular cells
Ductography	Ectatic ducts	Intraluminal mass
Fine-needle aspiration	Cystic lesion, no residual mass, no blood on aspiration	Hard lesion; malignant glandular cells
Mass	Biopsy	Biopsy
Follow-up	No mass: re-examine every 4mo and take annual mammogram	

			Symptomatic (%)				
	Patients with	Patients with Specific					
Specific Condition	MDAIDS (n)	Condition (n)	Occurrence				
Nipple Discharge							
Asymptomatic	103	8	8				
Symptomatic	577	238	41				
Nipple							
nversion/Retraction							
Asymptomatic	103	7	7				
Symptomatic	668	319	48				
Pain and Tenderness							
Asymptomatic	103	12	12				
Symptomatic	183	84	44				
Mass (Periareolar)							
Asymptomatic	103	33	32				
Symptomatic	399	203	51				
Abscess							
Asymptomatic	103	1	1				
Symptomatic	803	124	15				
Fistula							
Asymptomatic	103	0	0				
Symptomatic	176	34	19				
Bilaterality							
Symptomatic	495	114	23				



Complicated Mastitis & Breast Abscess

- Diagnostic and therapeutic challenge
- · No consensus on optimal management strategies

Subareolar And Recurrent Abscess

- Penultimate Stage In The Pathophysiology Of MDAIDS
 Mixed Organisms (Anaerobes)
 Rapid Onset Of Breast Pain, Tenderness And Swelling Of Central Subareolar Tissue
 History Of Similar Problems
 Resolution Of Symptoms Followed By Asymptomatic Interval (Months / Years) Followed
 Programmer
- by Necurrence
 Physical Findings Of Tenderness, Swelling, Erythema, Sloughing Of Skin, And Induration
 Or Fluctuation
 With Chronic, Recurrent Abscesses: Periareolar Fistula

•Treatment Plan
•If the abscess is in its early stages (consisting of an indurated mass), a 2-week course of
antibiotics consisting of a cephalosporin and metronidazole, elective excision is planned
for 2 to 4 weeks after resolved

for 2 to 4 weeks after resolved

-Mature Abscess
-If the abscess is fluctuant or has already drained spontaneously, treatment with the
patient under general anesthesia consists of making a wide incision to obtain effective
drainage and to culture the pus. The patient is then given the two antibiotics for 10 days
and monitored weekly to ensure satisfactory resolution with healing. Operative treatment
of the abscess and the associated duct under general anesthesia is then planned for 4 to
6 weeks later.
-Nonsurgical Management

Presentation

Symptoms: skin ervthema

- palpable mass
- tenderness
- · fever
- pain

· most commonly women between 20 and 50 years of age

Nonlactational

centrally (subareolar or periareolar)

periphery of the breast (upper outer quadrant)

er C.F.: Diseases of the breast, 2nd ed. Philadelphia, JB Lippincott, 1948. ockerty M.B., Harrington S.W.: Comedomastitis: A clinical and pathologic study of sata in 172 cases. Surg

Association With Breast Cancer

Initial Presentation:

Inflammatory changes may be the initial presentation of a breast cancer ALWAYS biopsy breast abscesses

Wound Infection After Lumpectomy For Breast Cancer:

• The incidence of acute infection following lumpectomy may be reduced by reapproximation of the deep breast tissue when possible.

Delayed breast cellulitis and abscesses: • external beam radiation therapy

- brachytherapy

Breast Lymphedema: • mild erythema

- edema
- secondary to treatment-related disruption of breast lymphatics
- typically self-limited (1 month to 1 year)

Evaluation

Clinical Examination

- erythema
- skin warmth · skin thickening
- tenderness

- adjunct to physical examinationhigh

- after successful management of acute breast infection or abscess
- to exclude malignancy

In the acute setting, abnormal mgm and US findings may be difficult to differentiate from malignancy

Microbiology

Staphylococcus aureus (most common organism)

Pseudomonas aeruginosa

Staphylococcus epidermidis

Serratia

Sterile on culture: (20 to 40%)

Cigarette smoking

- increased rates of anaerobic breast infections
- increased rates of recurrent breast abscess

- Body Art (nipple piercing and tattoos)

 Incidence as high as 10% to 20% in the months following the procedure
- organisms include aerobic, anaerobic, and mycobacterial infections

Unusual Breast Infections

Unusual Pathologic Organisms: (endemic to specific areas and specific patient populations)
-Actinomyces species

- *Brucella
 *Mycobacterium tuberculosis
 *Fusarium solani
- Echinococcus ·Cryptococcus
- ·Paragonimus

Necrotizing Soft Tissue Infection And Gangrene Of The Breast

- polymicrobial in etiology
 associated with anticoagulant treatment, trauma, and in the postpartum
- period
 management similar to other areas:

 - early diagnosis
 early and aggressive surgical management
 systemic antibiotics
 broad-spectrum antibiotics

Breast Cancer Vs Mastitis/Abscess

- Breast cancer
- · squamous cell carcinoma
- incidence of 4% (routine biopsy of the abscess cavity)
- · percutaneous management for selected cases is acceptable
- · failure to resolve symptoms should prompt tissue biopsies to exclude malignancy

Scott B.G., Silberfein E.J., Pham H.O., et al: Rate of malignancies in breast abscesses and argument of ultrasound drainage. Am J Surg 2006; 192:869-872

Periareolar Fistula

atients presenting with the other features of MDAIDS (i.e., nipple discharge, breast pain, varying degrees of ipple retraction, and acute subarceolar abscess refrequency of fistula related to a breast abscess varies from 4% to 20% lost of the tracts studied are lined by granulation lissue. Ell in only a few was squamous metaplasia found

istory should emphasize frequency and time intervals of antecedent acute subareolar abscesses or a suba flammatory mass that had either discharged spontaneously or had been surgically incised and drained lipple discharge, inpiple retraction, a history of lactation, and breast biopsies, patient's smoking

On physical examination, the site and location of the fistula opening in the involved breast should be noted. Both preasts should be inspected for nipples are retracted., subareolar masses, nipple discharge, or discharge from the istula of the involved breast.

reatment Plan unblibitios: The fistula tract into the subarcolar-retronipple space should be excised, together with the duct (ductectomy) as it merges through the nipple. The resulting wound is left open and loosely packed or closed primarily, w

Management

king is to this approach may include need for general anesthesia, high cost, and cosmetic deformity er rates between 10% and 38% requiring additional procedures the abscess cavity wall abscess resolution, mammography and breast ultrasound to exclude malignancy

ation is an alternative to primary surgical management (lactational and nonlactational abscesses)
nesis, lack of requirement for general anesthesia, no requirement for wound packing, and decreased cost
with single and multiple aspirations of breast abscess are 57% to 197% and 90% to 95%
e with multiple aspirations or whose clinical condition deteriorates require operative drainage and/or tissue biopsy

que : 16-gauge needle (or larger if necessary) with aspiration and irrigation of the cavity through an area where the skin is not out to guide aspiration is associated with higher rates of success but is not required utilitations as a component of initial therapy for breast abscess managed with aspiration so of aspirated folior may be useful to guide ambiliotic days.

Following initial management, patients should undergo clinical reassessment to determine reatment (repeat aspiration or surgical drainage) Median time to resolution of breast abscess with aspiration is 2 weeks (range, 1–7 weeks)

Factors that have been associated with failure of aspiration include large size (>-3cm) and loculations Progression or failure of symptoms to improve with serial aspirations mandates surgical management as outlined previously

Management

Antibiotics

- •no or a small fluid collection (PE/US)
- ·best directed by local antibiograms

CANTIA	Susceptible, Gram-negative bacili 1.01/10 - 12/31/18												
	AMK.	A/S	AZM	492	PER	CAL	CTA	QEN!	IMI	PIP/TAZ	TIG.	OT/II	1,000
Enterobacter épades	100	No.		1.0	06	70	72	04	98	10.01	- 4	10.02	8.0
	00				98	77.	79	94	1.66	84		95	91
Eatherichia coli	100	45	86"	857	96	94	94	87	100	954	100	87	- 64
The second secon	100	49	100	80	- 96	92	941	88	100	800	100	69	60
Klebsiella praumociae	100	n7	100	V 05 X	107.00	96	96-	07	1100	- 94	100	007	0.4
	100	83	100%	08	54	91	94:	97	100	06	99	87-	88
Proteus species	100	86		90	90	98	98	76	COPPOSE N	97	-	64	63
	100	04	100	100	100	100	100	04	10750	100		60	74
Pseudomonas aerugmosa	37		40		54	60		35	55	50		100	36
	87	-	331	100	74	86	0	69	79	- 85	-	0	88
	89	(m	100		75	79	0	80	77	79		2	50
Serratia marcescens	100		1001	10 K 1 Miles	-07	95	1.98	97	97	97	100	96	36
Morganella morganii	100	-		DOY YOU	100	201	100	98	100	190	100	73	62
Acinetobacter species	89	751	10-11	100	64	50		86	74	40		54	63
Circobacter fraundi	100	W.C.	No.	-0	100		80	92	100	COMP.	100	79	83
Circhischer kosen	100		DE SE	100	100	100	100	100	100		100	100	100
	-			No.	and the same					from papers			
	CAZ	TITLE	10 V 10 K	MOS	MEA	T/CU							
Burkhoderia cepacia	68	-71	233	1010	82.0	92			- Susc	apatisky rate	NY Caro	oxecin pr	1
Stanomonosa matophila	40	88	77.	m) (c)		34		similar to those of Levolioxacin					
- + Not reported				0.000									
	Suscept	ible, Gr	im-posit	we speci 1	/01/10 · 12	(31/10		10.1	100				
	AMP	CLIS	CLN	ane	GEN SNG*	OXA	LEV	TET	Ties	VAN	PON	LZO	BY
Staphylococcus aureus	Here was	Married Co.	72	727.0		603	69	1028	18	100	11	100	
Coag-rieg-stach species	100	7500	57	33		26	28	70	641	90	- 5		-
Enterpoocous faecium	8	9911	8		98	1		-		24	- 6	99****	03*
Enterococcus faecals	98	100		-	60	-		1	1	90	98	-	-
Streptococcus pneumoniae		07	69	40		N COL	89		-64	100			166
Not Reported Installation 1976's of locketes tested 51.75's of locketes tested 25.50's of locketes tested 25.50's of locketes tested 25.50's of locketes tested			iported o	n Varncomyo	oin Resista	nt Entire			-				

Antibiotic Regimen Cost Analysis							
The second	Dred.	Does	WFrequency !	COALTHE			
AMK	Amharin	Silving	DHI	80.04			
AMP	Ampromis	P per line	1999	870.16			
A/S	Annicht / Subartam	D amil	Diff	8130.4000			
AZM	A/Feoriam:	A per	QHI	\$50.07			
CFX	Calazotin	1 pm	1284	80.07			
FRIF	Cufuphine	Lpn	QUIII	\$50.12			
***	Colophine	200	Other	585.16			
CTX	Celotatione	Lpin	ORH	\$3.45			
OTX	Cultidarphia	I gin	ORI	\$8.47			
4	Celositro	100	Q6A	\$26.00			
CAZ	Conscience	Egn	GRH	823.79			
CIN	Celtiaxine	Ign	Q2494	\$10.29			
CLH	Chloramphinacol	11 gra	OBH	\$70.32			
014	Cleubarrycki	900 esp	ORH	\$44.43			
NYO	Datto/Gutto	500 mg	GiBt	Bentan			
AVC	DattoChrist	501 mg :	Othe	8331.64			
ENV	Erythology.	500 mg	Geri	841.00			
GEN	Contamen	80 mg	QBH	83.03			
16.01	Imperent/Sastem	500 Hg	QEH	E79.20			
LEV	Lendonson	500 mg	00	\$10.80			
120	Liverable	000 mg	QUIL	\$190.00			
MER	Meropotem						
-	Metropisatole	1 pm	OHI	\$84.33			
tios		500 mg	OHH	\$4.46			
A A SECTION AND	Minacycline	-	- H				
OXA	Holetto	2.00	(0)01	\$119.22			
	Disciple		5345				
PON	Position	100	OHI	3-90.00			
PHYTAE	Programmy Taxob	30.3	GH	\$50.52			
PIP/TAZ	Piperschistliosob	AND	OBH	B71.10			
Militar Company	Terracycline	1	1				
TICL	Trianshrychysanic	3.1 (85)	QB(875.90			
110	Tipicycline	60 mg	QUIN	\$120.48			
ALC: UNKNOWN	National	00 mg	ORH	83.00			
D)T/A	Timehopmy/sulan	350/1750 (Hg	Offi	254.64			
VAN	Stendamyoln	Section 1	Q12H	\$16.00			

Management - Aspiration

- •Alternative To Surgical Management (Lactational And Nonlactational Abscesses)
- Benefits: Cosmesis, Avoid General Anesthesia, No Wound Packing, Decreased Cost
- Success Rates:
 - Single Aspiration: 57% to 79%
 - Multiple Aspirations : 90% to 96%
- Fail To Improve = Operative Drainage And Tissue Biopsy

Leborgne F., Leborgne F.: Treatment of breast abscesses with conographically guided aspiration, irrigation, and instillation of antibiotics. AIR Am v Foentgenol 2003; 181:1083-1091. Scott B.G., Silbertein E.J., Pham H.O., et al: Rate of midignancies in Breast abscesses and argument for ultrasound drainage. Am J Surg 2006; 192:369-572. Schwarz F.J., Shrestin B.: Needle aspiration of breast abscesses. Am J Surg 2001; 182:117-119.

Management - Aspiration

Toobnigu

- * 16-gauge needle with aspiration and irrigation of the cavity through an area where the skin is not thinned from inflammation
- -ultrasound to guide aspiration is associated with higher rates of success but is not required
- •oral antibiotics as a component of initial therapy for breast abscess managed with aspiration
- •Cultures of aspirated fluid may be useful to guide antibiotic choice
- -Following initial management, patients should undergo clinical reassessment to determine resolution of requirement for additional treatment (repeat aspiration or surgical drainage).
- •Median time to resolution of breast abscess with aspiration is 2 weeks (range, 1–7 weeks)
- -Factors that have been associated with failure of aspiration include large size (>3cm) and loculations
- •Progression or failure of symptoms to improve with serial aspirations mandates surgical management as outlined previously
- Hallagement as dumined provided to the Leborgne F., Leborgne F., Leborgne F., Leborgne F., Leborgne F. Treatment of breast abscesses with sonographically guided aspiration, irrigation, and instituation of antibiotics. AJR Am J Roentgenol 2003; 181:1083-1091.

 Scott B.G., Silberfein E.J., Pham H.G., et al: Rate of malignancies in Breast abscesses and argument for ultrasound drainage. Am J Surg 2006; 192:809-872.

 Schwarz R.J., Shrestha R.: Needle aspiration of breast abscesses. Am J Surg 2001; 182:117-119.

Management

Surgical Incision and Drainage

- ·surgical incision
- disruption of septae
- •open packing
- limitations to this approach may include need for general anesthesia, high cost, and cosmetic deformity
- •recurrence rates between 10% and 38% requiring additional procedures
- ·biopsy of the abscess cavity wall
- •following abscess resolution, mammography and breast ultrasound to exclude malignancy

